PulseSight Therapeutics reported new quantitative imaging findings from its phase 1 study of PST-611 in geographic atrophy (GA), with a post hoc analysis showing reduced growth rates across several optical coherence tomography (OCT) biomarkers after treatment.

PST-611 is a nonviral gene therapy designed to express transferrin and address iron dysregulation implicated in GA. The first-in-human study enrolled 6 patients with advanced dry age-related macular degeneration across 2 dose cohorts. Its primary objective was to evaluate the safety and tolerability of a single PST-611 administration over 4 months. Safety results and preliminary observations suggesting changes in GA progression were previously presented at the 2026 meeting of the Association for Research in Vision and Ophthalmology.

For the analysis presented at the Euretina Congress in Vienna, PulseSight used RetinAI Discovery and artificial intelligence models to evaluate 4 structural biomarkers before and after treatment. The company reported early structural signals in 5 of 6 patients.

Across the 6-patient population, mean biomarker growth rates were 35% to 52% lower during the 4 months after treatment than during the pretreatment period. Retinal pigment epithelium depletion growth rate decreased by 40%, while ellipsoid-zone depletion and thickness-loss rates decreased by 35% and 52%, respectively. RP